SINOPHARM(CNCM LTD)(SH:600511) Shang Hai Zheng Quan Bao·2025-09-02 20:27Core Viewpoint - The announcement details the change of the continuous supervision representative for the equity division reform of China National Pharmaceutical Group Corporation (国药股份) due to the retirement of the previous representative, Liu Xiangsheng, and the appointment of Lu Wenjun as his successor [1][2]. Group 1 - The company received a letter from the underwriting sponsor, Shenwan Hongyuan Securities, regarding the change of the continuous supervision representative for the equity division reform project [1]. - Liu Xiangsheng will no longer continue his duties due to retirement, and Lu Wenjun will take over the responsibilities [1]. - The board expresses gratitude for Liu Xiangsheng's contributions during his tenure [2]. Group 2 - Lu Wenjun has a master's degree and 16 years of experience in investment banking, having participated in various IPOs and financial advisory projects [4].